Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
Bert H O'NeilJohn M WallmarkDavid LorenteElena ElezJudith RaimbourgCarlos Gomez-RocaSamuel EjadiSarina A Piha-PaulMark N SteinAlbiruni R Abdul RazakKatia DottiArmando SantoroRoger B CohenMarlena GouldSanatan SarafKaren SteinSae-Won HanPublished in: PloS one (2017)
Pembrolizumab demonstrated a favorable safety profile in advanced PD-L1-positive CRC. Antitumor activity was observed in a single patient with MSI-high CRC, warranting further evaluation in this patient population. (Clinicaltrials.gov registration: NCT02054806).